Natalizumab is an antibody directed against integrin alpha4 that reduces disease activity in patients with multiple sclerosis (MS) by blocking migration of T and B cells into the Central Nervouse System (CNS). The goal of this study was   more »

Thank you for your comment on my blog. I did not write that article. I reported it from Associated Press - Jun. 29, 2009. I put Associated Press - Jun. 29, 2009 on the bottom of the article to indicate that I did not write it. But   more »

company said late Friday it confirmed the presence of progressive multifocal leukoencephalopathy, or PML, on Tuesday. Biogen said the patient, who lives outside the U.S., had been using Tysabri for 30 months. Three of the ten   more »

The risk of developing progressive multifocal leukoencephalopathy (PML), a viral brain infection, in patients with multiple sclerosis (MS) taking the drug natalizumab (Tysabri) appears to be much lower - and the infection   more »

Researchers at Aurora St. Luke's Medical Center have developed a technique that counteracts an unusual, but serious, side effect from natalizumab (Tysabri®), a drug that   more »

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced five-times as many multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) were free from disease activity versus placebo in the overall patient population. Results   more »

Biogen Idec, Elan's partner in the development and sale of Tysabri, is testing the efficacy of a malaria pill developed during the Vietnam war in treating progressive multifocal leukoencephalopathy (PML), the brain infection that has been tied to use of Tysabri, according to Al Sandrock, Biogen's head of neurology   more »

Biogen Idec Inc (BIIB.O: Quote, Profile, Research, Stock Buzz) said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the   more »

To determine the safety, effectiveness, and tolerability of natalizumab use in pediatric   more »

A drug used to treat multiple sclerosis might make some patients vulnerable to brain infection by reducing the number of immune cells there, researchers at UT Southwestern Medical Center have found. The findings also suggest that the drug, Natalizumab (Tysabri), might be safer and   more »

Dear Healthcare Professional, Biogen ldec and Elan are writing to inform you of new safety information regarding TYSABRI" (natalizumab). The full Prescribing Information has been revised to add to the   more »

A letter posted to the Food and Drug Administration's Web site says that patients taking Tysabri, which is manufactured at a facility in Research Triangle Park, have developed signs of liver injury as soon as six days after taking their first dose.   more »

Q. Where can I call to get more information about Tysabri? The Tysabri Care Program is a registry that supports the safe and effective use of Tysabri. Its goals are to: · To inform people about the risks and benefits of Tysabri prior to treatment   more »

Q. Will my insurance cover the cost of Tysabri? A. According to Biogen Idec Canada, most private insurers are now reimbursing the cost of Tysabri. Generally insurance companies require prior authorization before they will   more »

Q. What is Tysabri (pronounced Tie-SAB-bree) and how does it work? A. Tysabri (whose scientific name is natalizumab, pronounced: nat-tal-IZ-zue-mab) is a laboratory-produced monoclonal antibody. It was formerly called Antegren. It had been approved for   more »